AUROBINDO PHARMA
AUROPHARMAVerifiedAUROBINDO PHARMA is a publicly traded security listed on the NSE/BSE exchange.
Stock Snapshot & Key Numbers — AUROBINDO PHARMA
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
AUROBINDO PHARMA (AUROPHARMA) is a Indian equity security listed on the NSE/BSE with ISIN BSE:524804. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹1666.90, recording a -11.00 (-0.66%) decline from its previous close of ₹1677.90. Over the trailing 52-week trading cycle, AUROPHARMA has traded between a 52-week low of ₹1085.00 and a 52-week high of ₹1734.00, establishing its annual trading channel. In historical performance, AUROBINDO PHARMA has gained 50.67% over the past 1 year. Period returns across standard measurement intervals include: 1-week: -1.54%, 1-month: +1.45%, 6-month: +20.22%, 1-year: +50.67%, 3-year: +83.28%, 5-year: +132.08%. Daily reported trading volume reached 7,96,734 equity shares. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of 26.4x and a price-to-book (P/B) ratio of 2.6x, with a trailing dividend yield of 0.00%. Its market capitalization stands at ₹97,411.48 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
Past Price Win/Loss Odds (1-Week, 1-Month, 3-Month)
How often this stock rose, stayed flat, or fell over past 21-day holding periods (based on historical data, not a future prediction).
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | +0.36 | +0.19 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a +0.36% co-movement (correlation: 0.19). Descriptive historical relationship, not predictive. |
| USD / INR | -0.15 | -0.04 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -0.15% co-movement (correlation: -0.04). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | -0.04 | -0.08 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.04% co-movement (correlation: -0.08). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | +0.06 | +0.03 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a +0.06% co-movement (correlation: 0.03). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹1,693.00 | ₹1,666.90 | -1.54% |
| 15 Days | ₹1,676.80 | ₹1,666.90 | -0.59% |
| 1 Month | ₹1,643.00 | ₹1,666.90 | +1.45% |
| 3 Months | ₹1,548.40 | ₹1,666.90 | +7.65% |
| 6 Months | ₹1,386.50 | ₹1,666.90 | +20.22% |
| 1 Year | ₹1,106.30 | ₹1,666.90 | +50.67% |
| 3 Years | ₹909.50 | ₹1,666.90 | +83.28% |
| 5 Years | ₹718.25 | ₹1,666.90 | +132.08% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹1,193.00 | ₹1,666.90 | +39.7% | |
| CY 2025 | ₹1,353.25 | ₹1,183.00 | -12.6% | |
| CY 2024 | ₹1,080.15 | ₹1,334.50 | +23.6% | |
| CY 2023 | ₹434.80 | ₹1,084.00 | +149.3% | |
| CY 2022 | ₹732.10 | ₹438.30 | -40.1% | |
| CY 2021 | ₹718.25 | ₹734.35 | +2.2% |
Historical Investment Simulator
Factual simulation of past returns in AUROBINDO PHARMA (AUROPHARMA) using real recorded closing prices.
Corporate Actions History
No dividend or stock split distributions recorded in historical feeds for AUROPHARMA.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27 - NDTV Profit
Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27 NDTV Profit
Aurobindo Pharma Q1 Results: Profit Jumps 25%, Revenue Rises To Rs 9,150 Crore; Margins Improve - NDTV Profit
Aurobindo Pharma Q1 Results: Profit Jumps 25%, Revenue Rises To Rs 9,150 Crore; Margins Improve NDTV Profit
Aurobindo Pharma Q1 results FY27: PAT Rs 1,033 Cr, Revenue Rs 9,1 - Univest
Aurobindo Pharma Q1 results FY27: PAT Rs 1,033 Cr, Revenue Rs 9,1 Univest
Aurobindo Pharma Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints - Univest
Aurobindo Pharma Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints Univest
Stocks to Watch Today: Aurobindo Pharma, Highway Infra, NCC, Blue Dart, Symbiotec Pharma, Shadowfax,... - Moneycontrol.com
Stocks to Watch Today: Aurobindo Pharma, Highway Infra, NCC, Blue Dart, Symbiotec Pharma, Shadowfax,... Moneycontrol.com
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Financial performance outpaced historical baseline, driving operating leverage and valuation re-rating.
- •Direct quantitative change registered at 2%
- •Financial performance and operating margins expanded ahead of consensus projections
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Continuous commercial tenders and capital expenditures lock in forward order book-to-bill expansion.
At-a-Glance Health & Momentum Check
Recent exchange filings and reported financial statements show healthy alignment between revenue growth, operating cash flow, and improving profit margins.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About AUROBINDO PHARMA (AUROPHARMA)
Key facts on AUROPHARMA share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of AUROBINDO PHARMA (AUROPHARMA)?
As of 16 Oct 2026, the official closing share price of AUROBINDO PHARMA (AUROPHARMA) on NSE/BSE is ₹1,666.90 (-0.66% vs the previous close). Over the past 52 weeks, AUROPHARMA has traded between a low of ₹1,085.00 and a high of ₹1,734.00, with a reported market capitalization of ₹97,411.48 Cr.
What are the historical returns of AUROBINDO PHARMA (AUROPHARMA)?
Based on split-adjusted closing prices through 16 Oct 2026, AUROBINDO PHARMA (AUROPHARMA) recorded the following trailing price returns: 1 Week: -1.54% (from ₹1,693.00 to ₹1,666.90); 15 Days: -0.59% (from ₹1,676.80 to ₹1,666.90); 1 Month: +1.45% (from ₹1,643.00 to ₹1,666.90); 3 Months: +7.65% (from ₹1,548.40 to ₹1,666.90); 6 Months: +20.22% (from ₹1,386.50 to ₹1,666.90); 1 Year: +50.67% (from ₹1,106.30 to ₹1,666.90); 3 Years: +83.28% (from ₹909.50 to ₹1,666.90); 5 Years: +132.08% (from ₹718.25 to ₹1,666.90). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of AUROBINDO PHARMA (AUROPHARMA)?
AUROBINDO PHARMA (AUROPHARMA) currently trades at a trailing Price-to-Earnings (P/E) ratio of 26.4x, a Price-to-Book (P/B) ratio of 2.6x, and a trailing 12-month dividend yield of 0.00%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in AUROPHARMA have grown?
Based on historical closing prices for AUROBINDO PHARMA (AUROPHARMA): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹2,32,077.97 (+132.1% total return, 18.4% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹6,10,000.00) would be worth ₹11,93,178.77 (+95.6% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.